Regulation of cardiac hypertrophy by microRNA-21
microRNA-21 对心脏肥大的调节
基本信息
- 批准号:7754005
- 负责人:
- 金额:$ 2.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-01-18 至 2012-12-17
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAffectAnimal ModelAutomobile DrivingCardiacCardiomyopathiesDataDiseaseDissectionEnhancersFutureGene ExpressionGene TargetingGenerationsGoalsHealth Care CostsHeart DiseasesHeart HypertrophyHeart failureHumanHypertrophyInvestigationKnockout MiceMessenger RNAMicroRNAsMolecularPathologicPathologic ProcessesPatternPlayProcessRegulationRegulator GenesRoleSmall RNAStressTranslationsUnited StatesUp-Regulationcardiogenesisin vivoinsightloss of functionmRNA Transcript Degradationmouse modelnoveloverexpressionpressurepreventresponsetherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Hypertrophic cardiac disease affects millions of people in the United States with total health care costs estimated in the billions of dollars. Investigation of the mechanisms that drive cardiac hypertrophy and remodeling are necessary in order to prevent and treat this disease. The long term goals of this project are to identify molecular mechanisms that drive this pathologic process, and to suggest new targets for the treatment of cardiac hypertrophy. MicroRNAs (miRs) have beeri strongly implicated in both heart development and disease. MiRs are small RNA molecules that decrease the expression of target genes by inducing sequence specific mRNA translational silencing or degradation. Specifically, miR-21 was identified as the most upregulated miR after pressure overload hypertrophy. Overexpression of miR-21 induces cardiac hypertrophy. These data strongly suggest that miR-21 plays a role in stress-induced cardiac hypertrophy and remodeling. This project will study the role of miR-21 in cardiac hypertrophy. This will be performed by investigation of the stress-responsive enhancer of miR-21. Characterization of this enhancer will suggest mechanisms that regulate the expression of miR-21 and thus implicate possible mechanisms of pharmacologic miR-21 modulation. The role of miR-21 in cardiac hypertrophy will be examined in vivo by generation of a miR-21 conditional knockout mouse. Both global and cardiac-specific deletion of miR-21 will allow for dissection of the role of this miR in stress-induced hypertrophy and remodeling. The mechanism of miR-21 induced cardiac hypertrophy will be determined. Determination of miR-21 target genes will suggest novel molecular mechanisms driving cardiac hypertrophy. These studies will provide insight into the mechanisms regulating cardiac disease, and they will define potential therapeutic targets for the future treatment of cardiac hypertrophy.
描述(由申请人提供):肥厚性心脏病影响着美国数百万人,医疗保健总费用估计达数十亿美元。为了预防和治疗这种疾病,有必要研究驱动心脏肥大和重塑的机制。该项目的长期目标是确定驱动这一病理过程的分子机制,并提出治疗心脏肥大的新靶点。 MicroRNA (miR) 与心脏发育和疾病密切相关。 MiR 是小 RNA 分子,可通过诱导序列特异性 mRNA 翻译沉默或降解来降低靶基因的表达。具体而言,miR-21 被确定为压力超负荷肥大后上调最多的 miR。 miR-21 的过度表达会诱导心脏肥大。这些数据强烈表明 miR-21 在应激诱导的心脏肥大和重塑中发挥作用。该项目将研究 miR-21 在心脏肥大中的作用。这将通过研究 miR-21 的应激反应增强子来完成。该增强子的表征将提示调节 miR-21 表达的机制,从而暗示药理学 miR-21 调节的可能机制。将通过生成 miR-21 条件敲除小鼠来体内检查 miR-21 在心脏肥大中的作用。 miR-21 的整体和心脏特异性删除将允许剖析该 miR 在应激诱导的肥大和重塑中的作用。 miR-21诱导心脏肥大的机制将被确定。 miR-21 靶基因的确定将揭示驱动心脏肥大的新分子机制。这些研究将深入了解调节心脏病的机制,并将确定未来治疗心脏肥大的潜在治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Patrick其他文献
David Patrick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Patrick', 18)}}的其他基金
A Role of Isolevuglandins in Essential Hypertension and Systemic Lupus Erythematosus
异黄兰素在原发性高血压和系统性红斑狼疮中的作用
- 批准号:
10513285 - 财政年份:2021
- 资助金额:
$ 2.8万 - 项目类别:
A Role of Isolevuglandin Adducts in Essential Hypertension and Systemic Lupus Erythematosus
异左旋黄素加合物在原发性高血压和系统性红斑狼疮中的作用
- 批准号:
10222781 - 财政年份:2020
- 资助金额:
$ 2.8万 - 项目类别:
A Role of Isolevuglandin Adducts in Essential Hypertension and Systemic Lupus Erythematosus
异左旋黄素加合物在原发性高血压和系统性红斑狼疮中的作用
- 批准号:
10038920 - 财政年份:2020
- 资助金额:
$ 2.8万 - 项目类别:
Isolevuglandin peptide modification and proteasomal processing is responsible for autoimmune mediated hypertension
异乌兰素肽修饰和蛋白酶体加工是导致自身免疫介导的高血压的原因
- 批准号:
9759492 - 财政年份:2019
- 资助金额:
$ 2.8万 - 项目类别:
Regulation of cardiac hypertrophy by microRNA-21
microRNA-21 对心脏肥大的调节
- 批准号:
8008777 - 财政年份:2010
- 资助金额:
$ 2.8万 - 项目类别:
Regulation of cardiac hypertrophy by microRNA-21
microRNA-21 对心脏肥大的调节
- 批准号:
8209106 - 财政年份:2010
- 资助金额:
$ 2.8万 - 项目类别:
相似海外基金
The mechanism of CELF1 upregulation and its role in the pathogenesis of Myotonic Dystrophy Type 1
CELF1上调机制及其在强直性肌营养不良1型发病机制中的作用
- 批准号:
10752274 - 财政年份:2024
- 资助金额:
$ 2.8万 - 项目类别:
CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease
CRISPR-Cas 编辑作为常染色体显性多囊肾病的基因治疗
- 批准号:
10822502 - 财政年份:2023
- 资助金额:
$ 2.8万 - 项目类别:
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
IL-17A mRNA 靶向寡核苷酸治疗特发性肺纤维化 (IPF)
- 批准号:
10761365 - 财政年份:2023
- 资助金额:
$ 2.8万 - 项目类别:
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.
SELENOF 是一种新型肿瘤抑制剂,也是克服乳腺癌种族差异的新靶点。
- 批准号:
10735662 - 财政年份:2023
- 资助金额:
$ 2.8万 - 项目类别:
miR-342, a novel glucocorticoid-responsive miRNA necessary for Foxp3+ regulatory T cell function
miR-342,一种新的糖皮质激素反应性 miRNA,是 Foxp3 调节 T 细胞功能所必需的
- 批准号:
10671943 - 财政年份:2023
- 资助金额:
$ 2.8万 - 项目类别: